Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions
CN109689057A
For treating the composition and method of metabolism disorder
AU2016206366A1
Parenteral formulations of dopamine agonists
AU2015201255A1
Parenteral formulations of dopamine agonists
AU2014265118A1
Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US2015024995A1
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US2014342975A1
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
CA2915405A1
Compositions and methods for treating metabolic disorders
AU2013263800A1
Methods of treating metabolic syndrome using dopamine receptor agonists
WO2012071295A1
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obestiy or prediabetes
BR112012031103A2
method of treating a patient suffering from a metabolic disorder, method of treating at least one non-metabolic disorder in one patient, method of treating at least metabolic disorder and at least non-metabolic disorder in one patient, method of treating at least one metabolic disorder a vascular disease in a patient and effective pharmaceutical composition to treat metabolic syndrome, type 2 diabetes, obesity, or pre-diabetes
BRPI1009619A2
pharmaceutical dosage form
ZA200908299B
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US2010035886A1
Parenteral formulations of dopamine agonists
WO2008157845A1
Method of treating metabolic disorders and depression with dopamine receptor agonists
EP1776955A1
Medical use and composition for the treatment of lipid and glucose metabolism disorders
